News | May 08, 2024
AstraZeneca completes equity investment agreement with Cellectis
Cellectis is also eligible to receive an investigational new drug (IND) option fee and development
Cellectis is also eligible to receive an investigational new drug (IND) option fee and development
Open a printable version of this pageEmail the URL of this page to a friend
The period from 2020 to 2022 witnessed a remarkable surge in deal worth
First and only long-acting C5 complement inhibitor offers patients with AQP4 Ab+
Currently, Sharma is a part of the Philippines Country Leadership Team as Business Unit Head Respiratory & Immunology
The agreement licenses the company to launch in the United States, in February 2025, once approved by the U.S. FDA
The U.S. FDA recently approved Xolair as the first and only medicine for children and adults with one or more food allergies
The acquisition of Healint aligns with Aptar Digital Health’s strategy to broaden its portfolio in neurology and strengthen its global footprint for digital health deployment
He is a former Neurology faculty member at The Johns Hopkins Hospital and an elected Fellow of the Royal College of Physicians, United Kingdom
Approval based on a separate phase III trial among Chinese patients reinforcing mepolizumab’s efficacy and safety data
Subscribe To Our Newsletter & Stay Updated
